Trial Profile

Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telmisartan (Primary) ; Telmisartan/verapamil (Primary) ; Verapamil (Primary)
Indications Panic disorder
Focus Adverse reactions; Therapeutic Use
Sponsors Honeybrains Biotech

Most Recent Events

18 Jun 2026 Status changed from recruiting to suspended. (Recruitment paused for Data Monitoring Committee (DMC) to review interim analysis data.)
10 Dec 2025 Planned End Date changed from 1 Feb 2026 to 1 Feb 2027.
10 Dec 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com